Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Shares Outstanding

Last Annual Value

10.61M

3-Year CAGR

10%

5-Year CAGR

11%

10-Year CAGR

6%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of shares-outstanding

NTRB · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
10.61M
10.1%6.0%5.8% 
129.86M
25.6%40.3%N/A
39.48M
9.5%17.6%29.3%
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
30.49M
0.1%0.3%-0.6%
38.51M
20.4%24.4%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
6.89M
36.8%28.9%-13.1%
32.97M
36.3%26.5%N/A
33.38M
10.3%15.2%32.5%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
230.35M
-22.1%-13.9%20.7%
IMA logo
ImageneBio Inc
NASDAQ:IMA
4.87M
-51.1%-33.0%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
15.57M
52.0%45.8%34.8%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15